Researchers analyzed data from the FDA Adverse Event Reporting System between April 2005 and September 2017 and found that older diabetes patients who used GLP-1 receptor agonists were not at an increased risk for diabetic retinopathy. The findings in Diabetes Care revealed that 263 of the 389 GLP-1 receptor agonist-related DR events were associated with exenatide, 82 with liraglutide, 28 with dulaglutide and 16 with albiglutide.
Endocrinology Advisor (1/1)
